1. Heparanase as a potential player in SARS-CoV-2 infection and induced coagulopathy.
- Author
-
Kinaneh S, Khamaysi I, Karram T, and Hamoud S
- Subjects
- Animals, Blood Coagulation Disorders blood, Blood Coagulation Disorders metabolism, COVID-19 blood, COVID-19 metabolism, Disseminated Intravascular Coagulation blood, Disseminated Intravascular Coagulation etiology, Disseminated Intravascular Coagulation metabolism, Heparan Sulfate Proteoglycans metabolism, Host-Pathogen Interactions, Humans, Virus Internalization, Blood Coagulation, Blood Coagulation Disorders etiology, COVID-19 complications, Glucuronidase metabolism, SARS-CoV-2 physiology
- Abstract
During the current formidable COVID-19 pandemic, it is appealing to address ideas that may invoke therapeutic interventions. Clotting disorders are well recognized in patients infected with severe acute respiratory syndrome (SARS) caused by a novel coronavirus (SARS-CoV-2), which lead to severe complications that worsen the prognosis in these subjects. Increasing evidence implicate Heparan sulfate proteoglycans (HSPGs) and Heparanase in various diseases and pathologies, including hypercoagulability states. Moreover, HSPGs and Heparanase are involved in several viral infections, in which they enhance cell entry and release of the viruses. Herein we discuss the molecular involvement of HSPGs and heparanase in SARS-CoV-2 infection, namely cell entry and release, and the accompanied coagulopathy complications, which assumedly could be blocked by heparanase inhibitors such as Heparin and Pixatimod., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF